First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
Author:
Affiliation:
1. UCB Pharma Slough UK
2. UCB Pharma Monheim Germany
3. PAREXEL International Middlesex UK
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13185
Reference31 articles.
1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
2. The Concise Guide to PHARMACOLOGY 2015/16: Overview
3. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors
4. The Burden of Moderate to Severe Psoriasis
5. Emerging topical treatments for psoriasis
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27
2. A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents;Journal of Dermatological Treatment;2023-11-15
3. Bimekizumab for the treatment of psoriatic arthritis;Expert Review of Clinical Immunology;2023-11-07
4. Sex-oriented perspectives in immunopharmacology;Pharmacological Research;2023-11
5. Data Extraction for Evidence Synthesis Using a Large Language Model: A Proof-of-Concept Study;2023-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3